<DOC>
	<DOC>NCT00728390</DOC>
	<brief_summary>This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given separately to patients in prior studies, and this study is to establish the safety and efficacy of the combination.</brief_summary>
	<brief_title>A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Histologically documented advanced cancer, Eastern Cooperative Oncology Group (ECOG) 01; Platelets &gt; 100,000, ANC &gt; 1500; Ccr &gt; 60 or serum creat. &lt;1.5 Nonsmall cell cancer cohort: Eastern Cooperative Oncology Group (ECOG) 02, prior platin, &lt; 4 prior chemotherapy regimen HgA1C &lt;5.7% Active Central Nervous System (CNS) metastases; prior IGF1R targeted therapy Any history of unstable angina, myocardial infarction or symptomatic congestive heart failure.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>advanced cancer refractory advanced non-small cell lung cancer</keyword>
</DOC>